secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-029078
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio restates 2022 interim financials due to R&D expense misclassification; expects material weakness
--------------------------------------------------------------------------------

- Material amounts of R&D expenses were misclassified as prepaid assets in Q1-Q3 2022 interim financials.
- Previously issued unaudited financials for March 31, June 30, and September 30, 2022 should no longer be relied upon.
- Company expects to report at least one material weakness in internal control over financial reporting.
- Restatements will be included in the 2022 Form 10-K; cash position for each period is not expected to change.
- Audit Committee and Board concluded restatement is appropriate after consulting with management and auditor WithumSmith+Brown.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923029078/0001104659-23-029078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923029078/tm238624d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer